NasdaqGS - Nasdaq Real Time Price USD

Solid Biosciences Inc. (SLDB)

2.7600

-0.0100

(-0.36%)

At close: May 9 at 4:00:01 PM EDT

2.8500

+0.09

+(3.26%)

After hours: May 9 at 7:36:13 PM EDT

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicabl

GlobeNewswire 9 days ago

SLDB
-0.36%
Solid Biosciences to Participate at The Citizens Life Sciences Conference

CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company websi

GlobeNewswire 10 days ago

SLDB
-0.36%
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 202

GlobeNewswire 11 days ago

SLDB
-0.36%
Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 24th Annual Needham Virtual Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present on Thursday, April 10, 2025, at 2:15 pm ET. A live webcast of the

GlobeNewswire last month

SLDB
-0.36%
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Boar

GlobeNewswire last month

VERV

IUGNF

ABOS
Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Solid Biosciences Inc. (NASDAQ:SLDB) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical […]

Insider Monkey last month

SLDB
-0.36%
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dalla

GlobeNewswire last month

SLDB
-0.36%
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

SLDB
-0.36%
SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.

Zacks 2 months ago

SLDB
-0.36%
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

- Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways - - FA: FDA Investigational New Drug (IND) clearance for first-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich’s ataxia (FA); Dosing of first participant anticipated in the second h

GlobeNewswire 2 months ago

SLDB
-0.36%
Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently?

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Solid Biosciences Inc. (NASDAQ:SLDB) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates a complex environment shaped […]

Insider Monkey 2 months ago

SLDB
-0.36%
Solid Biosciences Inc.'s (NASDAQ:SLDB) stock price dropped 11% last week; individual investors would not be happy

Key Insights Solid Biosciences' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 2 months ago

SLDB
-0.36%
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

Zacks 2 months ago

MRNA

SLDB
-0.36%

GILD
Solid Biosciences’ stock soars on early success in DMD gene therapy trial

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Clinical Trials Arena 2 months ago

SLDB
-0.36%
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering

Solid Biosciences (SLDB) shares were up almost 34% in Tuesday trading after the company said a phase

PREMIUM
MT Newswires 2 months ago

SLDB
-0.36%
Solid Biosciences Announces Pricing of Underwritten Offering

CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of

GlobeNewswire 2 months ago

SLDB
-0.36%
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February

GlobeNewswire 2 months ago

SLDB
-0.36%
Solid says early data suggest ‘differentiated’ Duchenne gene therapy

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.

BioPharma Dive 2 months ago

SLDB
-0.36%
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ‘Magnificent 7’ dominate the spotlight, the real hidden opportunities often lie in lesser-known stocks trading for $5 or less. These low-cost shares – penny stocks – may be cheap, but their potential can be massive. Many operate at the cutting edge of their industries, and when they hit the right catalyst – be it a breakthrough innovation or a disruptive product – their share prices

TipRanks 2 months ago

FHTX

SLDB
-0.36%
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s, AAV-based gene therapy candidat

GlobeNewswire 3 months ago

SLDB
-0.36%

Performance Overview

Return	SLDB	S&P 500 (^GSPC)
YTD	-31.00%	-3.77%
1-Year	-73.31%	+8.55%
3-Year	-64.27%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Solid Biosciences Inc. (SLDB)

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

Solid Biosciences to Participate at Upcoming Investor Conferences

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently?

Solid Biosciences Inc.'s (NASDAQ:SLDB) stock price dropped 11% last week; individual investors would not be happy

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

Solid Biosciences’ stock soars on early success in DMD gene therapy trial

Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Performance Overview